Showing results (11-20 of 746) with videos related to
Sort By:
Pageof 75
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 4, 2008
The risks and incidence of K65R and L74V mutations and subsequent virologic responsesLaura Waters, Mark Nelson, Sundhiya Mandalia, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|April 9, 2009
The nucleoside backbone affects durability of efavirenz- or nevirapine-based highly active antiretroviral therapy in antiretroviral-naive individualsNaa Torshie Annan, Mark Nelson, Sundhiya Mandalia, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|December 17, 2004
Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control studyRachael Jones, Justin Stebbing, Mark Nelson, et al.The Journal of Antimicrobial Chemotherapy|February 6, 2004
A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART)Justin Stebbing, Mark Nelson, Chloe Orkin, et al.The Medico-Legal Journal|June 11, 2014
Cancer: Where were we, where are we, where are we goingJustin StebbingAntiviral Research|March 10, 2010
Clinical outcome in resistant HIV-2 infection treated with raltegravir and maravirocDarius Armstrong-James, Justin Stebbing, Andrew Scourfield, et al.International Journal of Cancer|March 10, 2005
Hepatitis C infection is not associated with systemic HIV-associated non-Hodgkin's lymphoma: a cohort studyLaura Waters, Justin Stebbing, Sundhiya Mandalia, et al.Leukemia & Lymphoma|June 30, 2004
Resolution of AIDS-related Castleman's disease with anti-CD20 monoclonal antibodies is associated with declining IL-6 and TNF-alpha levelsTom Newsom-Davis, Mark Bower, Adrian Wildfire, et al.Blood|February 20, 2009
Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman diseaseMark Bower, Ophelia Veraitch, Richard Szydlo, et al.Pageof 75